As capital gains and dividend income are not taxed in a TFSA (Tax-Free Savings Account), investing in stocks through this route enhances the actual returns in the long term. Though the current macro environment and uncertainty related to it make investing tough, now is an opportune time to put your TFSA cash to work.
TFSA investors can buy high-quality stocks cheap and stay invested for a considerable amount of time to gain from the appreciation in their price. Along the way, investors can make regular income through stocks that offer reliable dividends.
So, if you plan to put your TFSA cash to work, consider investing in these under-$30 TSX stocks now to beat the market averages by a wide margin.
Telecom giant Telus (TSX:T)(NYSE:TU) is a solid investment to capitalize on the 5G trend and generate regular dividend income. Telus is known for consistently delivering profitable growth, enabling it to invest in growth initiatives and return higher cash to its shareholders.
It continues to strengthen its competitive positioning through the accelerated broadband investment program. Further, its focus on expanding the PureFibre network, 5G capabilities, connectivity, and copper to fibre migration bode well for growth. These initiatives will drive its customer base, lower churn, improve operating efficiency, and support cash flow growth.
Telus offers strong growth and a lucrative dividend yield of 4.6%. The company has paid about $16 billion in dividends since 2004. Further, through its dividend-growth program, Telus targets high-single-digit dividend growth through 2025.
WELL Health (TSX:WELL) offers digital healthcare services and growing its business rapidly. Despite concerns around its growth amid economic reopening, WELL Health has continued to deliver robust top-line growth on the back of solid organic sales and benefits from acquisitions.
It continues to benefit from higher omnichannel patient visits. For context, WELL delivered record second-quarter (Q2) revenues (up 127% year over year), driven by a 49% increase in omnichannel patient visits. Given the strength in its business, WELL Health has raised its 2022 revenue guidance for the third time, which should renew investors’ optimism in its stock.
WELL Health has been delivering positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) for the past several quarters and expects to deliver positive adjusted net income in 2022.
The ongoing momentum across online and in-person care channels will drive its organic growth. Further, the strength in its U.S.-based virtual patient services businesses will likely supplement its growth.
Despite the ongoing geopolitical and inflationary pressure, WELL Health doesn’t see any challenges to its business. It expects to deliver revenues of over $550 million in 2022. Further, it expects to generate about $100 million in adjusted EBITDA. Overall, its robust omnichannel patient visits, focus on accretive strategic acquisitions, and strength in its base business provide a multi-year growth foundation.
Telus and WELL Health’s growth runway looks good, and these under-$30 TSX stocks are poised to deliver solid growth. Both companies’ businesses are growing fast, while they have multiple catalysts to fuel the next leg of growth.